Abstract: The most frequently encountered RAMs are M204V/I: 48.8%, L180M: 33.3%, L80V: 28.8%, and V173L: 42.2%.
Result: M204V/I: 48.8%, plus L180M: 33.3% +- L80V: 28.8% and V173L: 42.2%:a profile suggestive for LAM resistance (with all mutations, except for M204V, also being associated with telbivudine resistance, and the combination of L180M, M204V, andV173L being associated with entecavir (ETV) resistance.
Discussion: In our study, despite the frequent association of the primary resistance mutations M204V/I with the compensatory
Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy.
Result: This phenomenon is consistent with previous report, demonstrating that the rtL180M mutation in HBV polymerase is commonly accompanied by rtM204V or rtM204I mutations.
Discussion: This assay is relative not sensitive compared to our cloning and sequencing analysis, and cannot discriminate whether the two rtM204V and rtM204I mutations are separately or simultaneously exist in the same HBV genome.
Dried blood spot sampling for hepatitis B virus quantification, sequencing and mutation detection.
Abstract: An HIV-coinfected patient presented the rtM204V/I-rtL180M double resistance mutation in serum and DBS.
Result: One patient had the double resistance polymerase mutation rtM204V/I-rtL180M, in both serum and DBS.
Discussion: Regarding resistance mutations, the double rtM204V/I-rtL180M mutation in polymerase gene (to lamivudine, telbivudine and entecavir:partial) was observed in both serum and DBS samples from an HIV-treated patient.
rt269I Type of Hepatitis B Virus (HBV) Polymerase versus rt269L Is More Prone to Mutations within HBV Genome in Chronic Patients Infected with Genotype C2: Evidence from Analysis of Full HBV Genotype C2 Genome.
Discussion: Indeed, we found several rt269I signature mutation types related to lower HBV replication (I84T/M/L/V in PreS1, preC-W28Stop, V/L5M in X region, C-I97F/L in C region and rtM204I/V in RT region) or liver disease progression (three types in preC/C region (preC-W28Stop, C-
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
Abstract: RAM M204I/V had the highest prevalence, occurring in 3.8% (109/2838) of all HBV sequences in our data set, and a significantly higher rate in genotype C at 5.4% (60/1102, p = 0.0007).
Discussion: A previous meta-analysis estimated the prevalence of M204I/V as 4.9% among >12,000 treatment-naive individuals, and another review reported a prevalence of M204I/V of 5.9% among 8435 treatment-naive individuals.
Discussion: For example, RAMs in HBV reverse transcriptase, A181T/V, M204I and M204V, cause corresponding changes in the overlapping region of HBsAg (W172 stop, W196S/L/Stop and PMID: 33758517
2021
Infection and drug resistance
Discussion: Three mutations associated with LAM resistance have been mostly described: rtM204V/I in C domain, rtV173L and rtL180M in B domain.
Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir.
Abstract: A recent Korean report showed that two patients with viral breakthrough during treatment with TDF-containing regimens were found to carry five reverse transcriptase (rt) mutations ([rt]S106C[C], rtH126Y[Y], rtD134E[E], rtM204I/V, and rtL269I [I]), with the C, Y, E, and I mutations being associated with tenofovir resistance.
Prevalence and characteristics of hepatitis B and D virus infections among HIV-positive individuals in Southwestern Nigeria.
Result: Amino acid substitutions were detected in the following frequency: rtM204V/I (9/31; 29.0%), rtL180M (8/31; 25.8%), rtV173L (7/31; 22.5%).
Result: No single mutation was detected while all amino acid substitutions were detected in combinations as rtL180M + rtV173L + rtM204V (n = 7/10), rtV173L + rtM204V (1/10), rtL180M + PMID: 32189364
2021
Hepatology (Baltimore, Md.)
Abstract: APPROACH AND RESULTS: In this study, we retrospectively monitored the emergence and reversion of the rtM204I/V mutant, a signature lamivudine resistance (LAMR ) mutation serving as a biomarker of cccDNA turnover in liver biopsies and longitudinal serum samples from two clinical trials.
Figure: Percentage of LAMR rtM204I/V mutation in serum and liver biopsy samples of 5 EFFORT patients collected at week 104 and 2 ML18376 patients collected at baseline (A).
Discussion: Last, patients with rtM204I/V develop VB with relatively high viral loads, which also facilitate the amplification and sequencing of LAMR in serum samples.
Discussion: Second, the development or reversion of the rt
HBV mutation literature information.
PMID: 
2022
Medicina (Kaunas, Lithuania)
Browser Board
Co-occurred Entities
Filtrator
ViMRT